Overexpression of IL-7 enhances cisplatin resistance in glioma

Cancer Biology and Therapy

Volumn 13, Issue 7, 2012, Pages 496-503

  Cui, Lei ^a,c   Fu, Jun ^a   Pang, Jesse Chung Sean ^b   Qiu, Zhi Kun ^a   Liu, Xiao Mei ^a   Chen, Fu Rong ^a   Shi, Hong Liu ^a   Ng, Ho Keung ^b   Chen, Zhong Ping ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

Author keywords

aCGH; Cisplatin; Glioma; IL 7; Resistance

Indexed keywords

CISPLATIN; INTERLEUKIN 7; MESSENGER RNA; RECOMBINANT INTERLEUKIN 7;

APOPTOSIS; ARTICLE; CANCER RESISTANCE; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; CYTOTOXICITY TEST; DRUG INHIBITION; FLOW CYTOMETRY; GENE DELETION; GENE IDENTIFICATION; GENE OVEREXPRESSION; GLIOMA; HUMAN; HUMAN CELL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; COMPARATIVE GENOMIC HYBRIDIZATION; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HUMANS; INHIBITORY CONCENTRATION 50; INTERLEUKIN-7; TRANSCRIPTION, GENETIC;

EID: 84861134494     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.19592     Document Type: Article

References (25)

1. Davis FG, Kupelian V, Freels S, McCarthy B, Surawicz T. Prevalence estimates for primary brain tumors in the United States by behavior and major histology groups. Neuro Oncol 2001; 3:152-8; PMID:11465395.
2. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al.; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352:987-96; PMID:15758009; http://dx.doi.org/10.1056/NEJMoa043330.
3. Shi Z, Liang YJ, Chen ZS, Wang XW, Wang XH, Ding Y, et al. Reversal of MDR1/P-glycoprotein-mediated multidrug resistance by vector-based RNA interference in vitro and in vivo. Cancer Biol Ther 2006; 5:39-47; PMID:16319528; http://dx.doi.org/10.4161/cbt.5.1.2236.
4. Huang J, Pang J, Watanabe T, Ng HK, Ohgaki H. Whole genome amplification for array comparative genomic hybridization using DNA extracted from formalin-fixed, paraffin-embedded histological sections. J Mol Diagn 2009; 11:109-16; PMID:19197000; http://dx.doi.org/10.2353/jmoldx.2009.080143.
5. Conze D, Weiss L, Regen PS, Bhushan A, Weaver D, Johnson P, et al. Autocrine production of interleukin 6 causes multidrug resistance in breast cancer cells. Cancer Res 2001; 61:8851-8; PMID:11751408.
6. Stassi G, Todaro M, Zerilli M, Ricci-Vitiani L, Di Liberto D, Patti M, et al. Thyroid cancer resistance to chemotherapeutic drugs via autocrine production of interleukin-4 and interleukin-10. Cancer Res 2003; 63:6784-90; PMID:14583474.
7. Wang Y, Qu Y, Niu XL, Sun WJ, Zhang XL, Li LZ. Autocrine production of interleukin-8 confers cisplatin and paclitaxel resistance in ovarian cancer cells. Cytokine 2011; 56:365-75; PMID:21742513; http://dx.doi.org/10.1016/j. cyto.2011.06.005.
8. Silva A, Gírio A, Cebola I, Santos CI, Antunes F, Barata JT. Intracellular reactive oxygen species are essential for PI3K/Akt/mTOR-dependent IL-7-mediated viability of T-cell acute lymphoblastic leukemia cells. Leukemia 2011; 25:960-7; PMID:21455214; http://dx.doi. org/10.1038/leu.2011.56.
9. Al-Rawi MA, Rmali K, Mansel RE, Jiang WG. Interleukin 7 induces the growth of breast cancer cells through a wortmannin-sensitive pathway. Br J Surg 2004; 91:61-8; PMID:14716795; http://dx.doi. org/10.1002/bjs.4449.
10. Karawajew L, Ruppert V, Wuchter C, Kösser A, Schrappe M, Dörken B, et al. Inhibition of in vitro spontaneous apoptosis by IL-7 correlates with bcl-2 upregulation, cortical/mature immunophenotype and better early cytoreduction of childhood T-cell acute lymphoblastic leukemia. Blood 2000; 96:297-306; PMID:10891465.
11. Prasad M, Bernardini M, Tsalenko A, Marrano P, Paderova J, Lee CH, et al. High definition cytogenetics and oligonucleotide aCGH analyses of cisplatin-resistant ovarian cancer cells. Genes Chromosomes Cancer 2008; 47:427-36; PMID:18273836; http://dx.doi.org/10.1002/gcc.20547.
12. Osterberg L, Levan K, Partheen K, Staaf J, Sundfeldt K, Horvath G. High-resolution genomic profiling of carboplatin resistance in early-stage epithelial ovarian carcinoma. Cytogenet Genome Res 2009; 125:8-18; PMID:19617691; http://dx.doi. org/10.1159/000218744.
13. Hattinger CM, Reverter-Branchat G, Remondini D, Castellani GC, Benini S, Pasello M, et al. Genomic imbalances associated with methotrexate resistance in human osteosarcoma cell lines detected by comparative genomic hybridization-based techniques. Eur J Cell Biol 2003; 82:483-93; PMID:14582536; http://dx.doi.org/10.1078/0171-9335-00336.
14. Struski S, Doco-Fenzy M, Trussardi A, Masson L, Gruson N, Ulrich E, et al. Identification of chromosomal loci associated with non-P-glycoprotein- mediated multidrug resistance to topoisomerase II inhibitor in lung adenocarcinoma cell line by comparative genomic hybridization. Genes Chromosomes Cancer 2001; 30:136-42; PMID:11135430; http://dx.doi. org/10.1002/1098- 2264(2000)9999:9999〈::AIDGCC1071〉 3.0.CO;2-T.
15. Holcomb IN, Young JM, Coleman IM, Salari K, Grove DI, Hsu L, et al. Comparative analyses of chromosome alterations in soft-tissue metastases within and across patients with castration-resistant prostate cancer. Cancer Res 2009; 69:7793-802; PMID:19773449; http://dx.doi.org/10.1158/0008-5472.CAN-08-3810.
16. Dimova I, Orsetti B, Negre V, Rouge C, Ursule L, Lasorsa L, et al. Genomic markers for ovarian cancer at chromosomes 1, 8 and 17 revealed by array CGH analysis. Tumori 2009; 95:357-66; PMID:19688977.
17. de Leeuw RJ, Davies JJ, Rosenwald A, Bebb G, Gascoyne RD, Dyer MJ, et al. Comprehensive whole genome array CGH profiling of mantle cell lymphoma model genomes. Hum Mol Genet 2004; 13:1827-37; PMID:15229187; http://dx.doi.org/10. 1093/hmg/ddh195.
18. Jiang Q, Li WQ, Aiello FB, Mazzucchelli R, Asefa B, Khaled AR, et al. Cell biology of IL-7, a key lymphotrophin. Cytokine Growth Factor Rev 2005; 16:513-33; PMID:15996891; http://dx.doi.org/10.1016/j.cytogfr. 2005.05.004.
19. Oka M, Hirose K, Iizuka N, Aoyagi K, Yamamoto K, Abe T, et al. Cytokine mRNA expression patterns in human esophageal cancer cell lines. J Interferon Cytokine Res 1995; 15:1005-9; PMID:8590302; http://dx.doi.org/10.1089/jir.1995. 15.1005.
20. Maeurer MJ, Walter W, Martin D, Zitvogel L, Elder E, Storkus W, et al. Interleukin-7 (IL-7) in colorectal cancer: IL-7 is produced by tissues from colorectal cancer and promotes preferential expansion of tumour infiltrating lymphocytes. Scand J Immunol 1997; 45:182-92; PMID:9042431; http://dx.doi. org/10.1046/j.1365-3083.1997.d01-384.x.
21. Takeuchi T, Yamanouchi H, Yue Q, Ohtsuki Y. Epithelial component of lymphoid stroma-rich Warthin's tumour expresses interleukin (IL)-7. Histopathology 1998; 32:383-4; PMID:9602344; http://dx.doi.org/10.1046 /j.1365-2559.1998.0401 h.x.
22. Paleri V, Pulimood A, Davies GR, Birchall MA. Interleukins 7 and 12 are expressed in head and neck squamous cancer. Clin Otolaryngol Allied Sci 2001; 26:302-6; PMID:11559342; http://dx.doi. org/10.1046/j.1365-2273.2001.00475.x.
23. Al-Rawi MA, Rmali K, Watkins G, Mansel RE, Jiang WG. Aberrant expression of interleukin-7 (IL-7) and its signalling complex in human breast cancer. Eur J Cancer 2004; 40:494-502; PMID:14962714; http://dx.doi.org/10.1016/j.ejca.2003. 10.016.
24. Zhao YP, Chen G, Feng B, Zhang TP, Ma EL, Wu YD. Microarray analysis of gene expression profile of multidrug resistance in pancreatic cancer. Chin Med J (Engl) 2007; 120:1743-52; PMID:18028764.
25. Sade H, Sarin A. IL-7 inhibits dexamethasone-induced apoptosis via Akt/PKB in mature, peripheral T cells. Eur J Immunol 2003; 33:913-9; PMID:12672057; http://dx.doi.org/10.1002/eji.200323782.